Can you take Deucravacitinib with Nilotinib?

Deucravacitinib has a moderate potential interaction with Bladder Cancer.

Malignancies including lymphomas were reported in clinical trials with deucravacitinib. Risks and benefits of each individual patient should be considered prior to treatment initiation, especially in patients with known malignancies (other than a successfully treated non-melanoma skin cancer).

Deucravacitinib has a moderate potential interaction with Breast Cancer.

Malignancies including lymphomas were reported in clinical trials with deucravacitinib. Risks and benefits of each individual patient should be considered prior to treatment initiation, especially in patients with known malignancies (other than a successfully treated non-melanoma skin cancer).

Nilotinib has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Cardiovascular events (including arterial vascular occlusive events, peripheral arterial occlusive disease, and ischemic cerebrovascular events) have been reported in patients receiving BCR-ABL tyrosine kinase inhibitors. Patients should seek immediate medical attention if acute signs or symptoms of cardiovascular events occur. Cardiovascular status should be evaluated, and cardiovascular risk factors should be monitored and actively managed during treatment.

Nilotinib has a moderate potential interaction with Electrolyte Abnormalities.

Nilotinib can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia. Electrolyte abnormalities should be corrected prior to initiating nilotinib and during therapy; these electrolytes should be monitored periodically during therapy.

Deucravacitinib has a moderate potential interaction with History, Skin Cancer.

Malignancies including lymphomas were reported in clinical trials with deucravacitinib. Risks and benefits of each individual patient should be considered prior to treatment initiation, especially in patients with known malignancies (other than a successfully treated non-melanoma skin cancer).

Nilotinib has a major potential interaction with Hypokalemia.

The use of nilotinib is contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome. Nilotinib prolongs the QT interval in a concentration-dependent manner; QT prolongation may lead to torsade de pointes, which can result in syncope, seizures, and/or death. Before initiating nilotinib and periodically, electrolyte, calcium, and magnesium blood levels should be tested. Hypokalemia or hypomagnesemia must be corrected before starting treatment and these electrolytes should be monitored periodically. ECGs should be obtained at baseline, 7 days after starting nilotinib, following dose adjustments, and periodically as clinically indicated.

Deucravacitinib has a moderate potential interaction with Infection.

Deucravacitinib increases the risk of infection and should be avoided in patients with active or serious infections. Clinical trials also reported cases of herpes virus reactivation. Patients should be screened for viral hepatitis and tuberculosis prior to initiating therapy with this drug, and should be monitored during treatment for infection reactivations or new infections. Any new infection should be promptly diagnosed and treated and the patient should be closely monitored. If a serious infection develops, discontinue treatment immediately until the infection is treated and resolved.

Nilotinib has a moderate potential interaction with Intestinal Anastomoses.

Nilotinib exposure is reduced in patients with total gastrectomy. More frequent monitoring of these patients is recommended; a dose increase or alternative therapy should be considered.

Nilotinib has a moderate potential interaction with Lactose Intolerance.

Nilotinib capsule formulations contain lactose and are not recommended for patients with rare hereditary problems of galactose intolerance, severe lactase deficiency with a severe degree of intolerance to lactose-containing products, or glucose-galactose malabsorption.

Deucravacitinib has a moderate potential interaction with Leukemia.

Malignancies including lymphomas were reported in clinical trials with deucravacitinib. Risks and benefits of each individual patient should be considered prior to treatment initiation, especially in patients with known malignancies (other than a successfully treated non-melanoma skin cancer).

Deucravacitinib has a moderate potential interaction with Liver Disease.

Deucravacitinib treatment has been associated with an increase in liver enzymes, in some cases greater than 3 times the upper normal limit (ULN). Liver enzymes should be evaluated at baseline and monitored thereafter in patients with known or suspected liver disease. If drug-induced liver injury is suspected, treatment should be interrupted until this diagnosis is excluded. Deucravacitinib is not recommended in patients with severe hepatic impairment.

Nilotinib has a moderate potential interaction with Liver Disease.

Nilotinib exposure is increased in patients with hepatic impairment. If possible, alternative therapies should be considered; if nilotinib use is necessary, the dosage should be reduced and the QT interval should be monitored closely. Nilotinib may cause hepatotoxicity as measured by elevations in bilirubin, AST, ALT, and alkaline phosphatase; liver function tests should be monitored monthly or as clinically indicated and after dosage adjustments.

Nilotinib has a major potential interaction with Long QT Syndrome.

The use of nilotinib is contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome. Nilotinib prolongs the QT interval in a concentration-dependent manner; QT prolongation may lead to torsade de pointes, which can result in syncope, seizures, and/or death. Before initiating nilotinib and periodically, electrolyte, calcium, and magnesium blood levels should be tested. Hypokalemia or hypomagnesemia must be corrected before starting treatment and these electrolytes should be monitored periodically. ECGs should be obtained at baseline, 7 days after starting nilotinib, following dose adjustments, and periodically as clinically indicated.

Deucravacitinib has a moderate potential interaction with Lung Cancer.

Malignancies including lymphomas were reported in clinical trials with deucravacitinib. Risks and benefits of each individual patient should be considered prior to treatment initiation, especially in patients with known malignancies (other than a successfully treated non-melanoma skin cancer).

Deucravacitinib has a moderate potential interaction with Lymphoma.

Malignancies including lymphomas were reported in clinical trials with deucravacitinib. Risks and benefits of each individual patient should be considered prior to treatment initiation, especially in patients with known malignancies (other than a successfully treated non-melanoma skin cancer).

Nilotinib has a major potential interaction with Magnesium Imbalance.

The use of nilotinib is contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome. Nilotinib prolongs the QT interval in a concentration-dependent manner; QT prolongation may lead to torsade de pointes, which can result in syncope, seizures, and/or death. Before initiating nilotinib and periodically, electrolyte, calcium, and magnesium blood levels should be tested. Hypokalemia or hypomagnesemia must be corrected before starting treatment and these electrolytes should be monitored periodically. ECGs should be obtained at baseline, 7 days after starting nilotinib, following dose adjustments, and periodically as clinically indicated.

Nilotinib has a moderate potential interaction with Pancreatitis.

Nilotinib can increase serum lipase. Patients with a history of pancreatitis may be at greater risk of elevated serum lipase. Serum lipase should be monitored monthly or as clinically indicated. If lipase elevations occur with abdominal symptoms, treatment should be interrupted and appropriate diagnostic evaluation should be considered to exclude pancreatitis.

Deucravacitinib has a moderate potential interaction with Prostate Cancer.

Malignancies including lymphomas were reported in clinical trials with deucravacitinib. Risks and benefits of each individual patient should be considered prior to treatment initiation, especially in patients with known malignancies (other than a successfully treated non-melanoma skin cancer).

Deucravacitinib has a moderate potential interaction with Rheumatoid Arthritis.

A large, randomized, postmarketing safety trial of a JAK inhibitor in rheumatoid arthritis (RA) patients 50 years old and older with at least one cardiovascular risk factor, reported higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) in patients treated with the JAK inhibitor compared to patients receiving TNF blockers. Deucravacitinib is not approved for use in RA.